StockNews.com Initiates Coverage on Tonix Pharmaceuticals (NASDAQ:TNXP)

Stock analysts at StockNews.com began coverage on shares of Tonix Pharmaceuticals (NASDAQ:TNXP) in a note issued to investors on Tuesday. The firm set a “sell” rating on the stock.

Separately, Alliance Global Partners lifted their price target on shares of Tonix Pharmaceuticals from $6.00 to $11.00 and gave the company a “buy” rating in a report on Monday, July 22nd.

Tonix Pharmaceuticals Price Performance

Shares of Tonix Pharmaceuticals stock opened at $0.14 on Tuesday. The business has a 50-day moving average price of $0.17 and a 200 day moving average price of $1.74. Tonix Pharmaceuticals has a fifty-two week low of $0.12 and a fifty-two week high of $22.14. The firm has a market cap of $19.46 million, a P/E ratio of 0.00 and a beta of 2.06. The company has a quick ratio of 0.72, a current ratio of 1.15 and a debt-to-equity ratio of 0.13.

Tonix Pharmaceuticals (NASDAQ:TNXP) last posted its quarterly earnings results on Friday, August 16th. The company reported ($19.28) earnings per share (EPS) for the quarter, missing the consensus estimate of ($9.91) by ($9.37). The firm had revenue of $2.21 million for the quarter, compared to analyst estimates of $3.50 million. Tonix Pharmaceuticals had a negative net margin of 1,196.11% and a negative return on equity of 158.27%. On average, sell-side analysts forecast that Tonix Pharmaceuticals will post -18 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Tonix Pharmaceuticals stock. Acadian Asset Management LLC lifted its position in shares of Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) by 260.6% in the 1st quarter, according to its most recent disclosure with the SEC. The fund owned 335,373 shares of the company’s stock after acquiring an additional 242,358 shares during the period. Acadian Asset Management LLC owned 0.40% of Tonix Pharmaceuticals worth $61,000 as of its most recent filing with the SEC. 82.26% of the stock is owned by institutional investors.

Tonix Pharmaceuticals Company Profile

Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults.